

Gerald A Soff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6597894/publications.pdf>

Version: 2024-02-01

57
papers

2,524
citations

361045

20
h-index

197535

49
g-index

57
all docs

57
docs citations

57
times ranked

2774
citing authors

#	ARTICLE	IF	CITATIONS
1	Romiplostim for chemotherapy-induced thrombocytopenia: Efficacy and safety of extended use. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12701.	1.0	6
2	Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH-ASCC subcommittee on hemostasis and malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1920-1927.	1.9	3
3	Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia. <i>PLoS ONE</i> , 2022, 17, e0257673.	1.1	7
4	Occurrence and Management of Thrombocytopenia in Metastatic Colorectal Cancer Patients Receiving Chemotherapy: Secondary Analysis of Data From Prospective Clinical Trials. <i>Clinical Colorectal Cancer</i> , 2021, 20, 170-176.	1.0	16
5	Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. <i>Blood</i> , 2021, 137, 2103-2113.	0.6	57
6	Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps. <i>Oncologist</i> , 2021, 26, e17-e23.	1.9	12
7	Laboratory evaluation of folate deficiency among inpatients with cancer. <i>International Journal of Laboratory Hematology</i> , 2021, 43, O164-O167.	0.7	0
8	A Review of Romiplostim Mechanism of Action and Clinical Applicability. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2243-2268.	2.0	35
9	Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. <i>Expert Review of Hematology</i> , 2021, 14, 437-448.	1.0	29
10	Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study. <i>Annals of Neurology</i> , 2021, 90, 159-169.	2.8	31
11	Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12549.	1.0	9
12	Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2021, 163, 36-40.	0.6	18
13	Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial. <i>TH Open</i> , 2020, 04, e107-e112.	0.7	16
14	Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 532-549.	1.0	10
15	Prediction of COVID-19 Mortality in Patients with Cancer. <i>Blood</i> , 2020, 136, 29-30.	0.6	0
16	Development and Baseline Characterization of a Thrombosis Risk Alert Tool: A Quality Assessment Project. <i>Blood</i> , 2020, 136, 18-19.	0.6	0
17	Machine Learning for Prediction of Cancer-Associated Venous Thromboembolism. <i>Blood</i> , 2020, 136, 37-37.	0.6	1
18	Management of Thrombocytopenia in Cancer Patients. <i>Cancer Treatment and Research</i> , 2019, 179, 139-150.	0.2	17

#	ARTICLE	IF	CITATIONS
19	Thrombosis and Hemostasis in Cancer. Scope of the Problem and Overview. Cancer Treatment and Research, 2019, 179, 1-9.	0.2	9
20	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2019, 20, e566-e581.	5.1	458
21	Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia. Journal of Clinical Oncology, 2019, 37, 2892-2898.	0.8	53
22	Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 349-356.	1.0	29
23	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. New England Journal of Medicine, 2019, 380, 720-728.	13.9	520
24	Extended Mutational Profiling By MSK-IMPACT™ Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy. Blood, 2019, 134, 633-633.	0.6	1
25	Anticoagulation in the Patient with Cancer. , 2018, , 425-440.		1
26	Predictive factors of fatal bleeding in acute promyelocytic leukemia. Thrombosis Research, 2018, 164, S98-S102.	0.8	16
27	NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1289-1303.	2.3	168
28	Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients With Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 670-673.	2.3	8
29	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). Blood, 2018, 132, LBA-1-LBA-1.	0.6	12
30	Safe and Effective Use of Rivaroxaban for Treatment of Cancer Associated Venous Thromboembolic Disease. Blood, 2018, 132, 2536-2536.	0.6	2
31	Cancer-Associated Thrombosis: Anatomic Distribution of the Index Event Is Not a Reliable Predictor of Recurrence Risk. Blood, 2018, 132, 1252-1252.	0.6	1
32	Folate Testing and Deficiency in Hospitalized Cancer Patients. Blood, 2018, 132, 5814-5814.	0.6	0
33	Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. Journal of Thrombosis and Thrombolysis, 2017, 43, 514-518.	1.0	65
34	Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer. American Journal of Cardiology, 2017, 120, 213-217.	0.7	44
35	Outcomes after inferior vena cava filter placement in cancer patients diagnosed with pulmonary embolism: risk for recurrent venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2017, 44, 489-493.	1.0	16
36	Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban. American Journal of Hematology, 2017, 92, E9-E10.	2.0	36

#	ARTICLE	IF	CITATIONS
37	Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 166-171.	1.0	84
38	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2135-2145.	1.8	53
39	Preoperative Chemoprophylaxis Is Safe in Major Oncology Operations and Effective at Preventing Venous Thromboembolism. <i>Journal of the American College of Surgeons</i> , 2016, 222, 129-137.	0.2	34
40	Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and Active Cancer. <i>Blood</i> , 2016, 128, 2621-2621.	0.6	2
41	Reduced Emergency Room Utilization for Initiation of Anticoagulation with Rivaroxaban Treatment of Cancer-Associated Thrombosis. <i>Blood</i> , 2016, 128, 2619-2619.	0.6	1
42	Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1079-1095.	2.3	100
43	Ovarian vein thrombosis after debulking surgery for ovarian cancer: epidemiology and clinical significance. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 208.e1-208.e4.	0.7	13
44	Reduced Emergency Room Utilization for Initiation of Anticoagulation with Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Thrombosis. <i>Blood</i> , 2015, 126, 2068-2068.	0.6	2
45	Enoxaparin Dose Reduction for Thrombocytopenia in Patients with Cancer: A Quality Assessment Study. <i>Blood</i> , 2015, 126, 429-429.	0.6	2
46	Safe and Effective Use of Rivaroxaban for Treatment of Cancer-Associated Venous Thromboembolic Disease: A Quality Improvement Initiative. <i>Blood</i> , 2015, 126, 431-431.	0.6	3
47	Outcomes of Inferior Vena Cava Filter Placement in a Large Population of Cancer Patients Diagnosed with Pulmonary Embolism: Risk for Recurrent Venous Thromboembolism, Survival, and Filter-Related Complications. <i>Blood</i> , 2015, 126, 1112-1112.	0.6	0
48	Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light chain (AL) amyloidosis. <i>American Journal of Hematology</i> , 2014, 89, 1153-1154.	2.0	7
49	Clinical consequences of an indeterminate CT pulmonary angiogram in cancer patients. <i>Clinical Imaging</i> , 2014, 38, 637-640.	0.8	13
50	Alternatively Spliced Tissue Factor Promotes Plaque Angiogenesis Through the Activation of Hypoxia-Inducible Factor-1 α and Vascular Endothelial Growth Factor Signaling. <i>Circulation</i> , 2014, 130, 1274-1286.	1.6	44
51	Commentary on "Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation". <i>Translational Research</i> , 2014, 163, 136-140.	2.2	2
52	Skin necrosis induced by generic enoxaparin. <i>American Journal of Hematology</i> , 2013, 88, 339-339.	2.0	6
53	Pathophysiology and management of thrombosis in cancer: 150 years of progress. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 346-351.	1.0	7
54	A New Generation of Oral Direct Anticoagulants. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 569-574.	1.1	31

#	ARTICLE	IF	CITATIONS
55	Combined factor V and factor VIII deficiency. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 474-6.	0.3	0
56	Disseminated Intravascular Coagulation with Excessive Fibrinolysis in Prostate Cancer: A Case Series and Review of the Literature. <i>Oncology</i> , 2011, 81, 119-125.	0.9	45
57	High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis. <i>Journal of Clinical Oncology</i> , 2011, 29, 3466-3473.	0.8	369